JP2004518702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004518702A5 JP2004518702A5 JP2002562729A JP2002562729A JP2004518702A5 JP 2004518702 A5 JP2004518702 A5 JP 2004518702A5 JP 2002562729 A JP2002562729 A JP 2002562729A JP 2002562729 A JP2002562729 A JP 2002562729A JP 2004518702 A5 JP2004518702 A5 JP 2004518702A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- thiazol
- phenoxy
- propionic acid
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- -1 4- (1- [2- (2-Fluoro-4-trifluoromethyl-phenyl) -4-methyl-thiazol-5-yl] -ethoxy) -2-methylphenoxy Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 claims 4
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 208000022531 anorexia Diseases 0.000 claims 3
- 206010061428 decreased appetite Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- ZUGQWAYOWCBWGM-UHFFFAOYSA-N 2-[4-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound CC=1N=C(C=2C(=CC(=CC=2)C(F)(F)F)F)SC=1CSC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 ZUGQWAYOWCBWGM-UHFFFAOYSA-N 0.000 claims 2
- RRDUKUBKIRKLQP-OAHLLOKOSA-N 2-methyl-2-[2-methyl-4-[(1r)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenoxy]propanoic acid Chemical compound O([C@H](C)C1=C(N=C(S1)C=1C=CC(=CC=1)C(F)(F)F)C)C1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 RRDUKUBKIRKLQP-OAHLLOKOSA-N 0.000 claims 2
- RRDUKUBKIRKLQP-HNNXBMFYSA-N 2-methyl-2-[2-methyl-4-[(1s)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenoxy]propanoic acid Chemical compound O([C@@H](C)C1=C(N=C(S1)C=1C=CC(=CC=1)C(F)(F)F)C)C1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 RRDUKUBKIRKLQP-HNNXBMFYSA-N 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000004494 ethyl ester group Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- AOUIGDBKRLOZRQ-UHFFFAOYSA-N 2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenoxy]acetic acid Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(C)OC1=CC=C(OCC(O)=O)C(C)=C1 AOUIGDBKRLOZRQ-UHFFFAOYSA-N 0.000 claims 1
- ACNJQJVNIHENMJ-UHFFFAOYSA-N 2-[4-[1-[2-(3,4-dichlorophenyl)-4-methyl-1,3-thiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound S1C(C=2C=C(Cl)C(Cl)=CC=2)=NC(C)=C1C(C)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 ACNJQJVNIHENMJ-UHFFFAOYSA-N 0.000 claims 1
- JDJCZGMWUDTZHP-UHFFFAOYSA-N 2-[4-[1-[2-(4-chlorophenyl)-4-methyl-1,3-thiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound S1C(C=2C=CC(Cl)=CC=2)=NC(C)=C1C(C)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 JDJCZGMWUDTZHP-UHFFFAOYSA-N 0.000 claims 1
- GALPDOKVVGMRBH-UHFFFAOYSA-N 2-[4-[1-[2-(4-ethylphenyl)-4-methyl-1,3-thiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound C1=CC(CC)=CC=C1C1=NC(C)=C(C(C)OC=2C=C(C)C(OC(C)(C)C(O)=O)=CC=2)S1 GALPDOKVVGMRBH-UHFFFAOYSA-N 0.000 claims 1
- LQAGUDSBCGFOHU-UHFFFAOYSA-N 2-[4-[1-[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound S1C(C=2C(=CC(=CC=2)C(F)(F)F)F)=NC(C)=C1C(C)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 LQAGUDSBCGFOHU-UHFFFAOYSA-N 0.000 claims 1
- SDXLGWSTXLUGHO-UHFFFAOYSA-N 2-[4-[1-[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound S1C(C=2C=C(F)C(=CC=2)C(F)(F)F)=NC(C)=C1C(C)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 SDXLGWSTXLUGHO-UHFFFAOYSA-N 0.000 claims 1
- ISQOFVFXEZIWTH-UHFFFAOYSA-N 2-[4-[cyclopentyl-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methoxy]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(C1CCCC1)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 ISQOFVFXEZIWTH-UHFFFAOYSA-N 0.000 claims 1
- GPDKHYMYBCWQSD-LJQANCHMSA-N 2-methyl-2-[2-methyl-4-[(1r)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propoxy]phenoxy]propanoic acid Chemical compound O([C@H](CC)C1=C(N=C(S1)C=1C=CC(=CC=1)C(F)(F)F)C)C1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 GPDKHYMYBCWQSD-LJQANCHMSA-N 0.000 claims 1
- GPDKHYMYBCWQSD-IBGZPJMESA-N 2-methyl-2-[2-methyl-4-[(1s)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propoxy]phenoxy]propanoic acid Chemical compound O([C@@H](CC)C1=C(N=C(S1)C=1C=CC(=CC=1)C(F)(F)F)C)C1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 GPDKHYMYBCWQSD-IBGZPJMESA-N 0.000 claims 1
- IZCWEGLTGIXGEK-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[1-[2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenoxy]propanoic acid Chemical compound C=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(C)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 IZCWEGLTGIXGEK-UHFFFAOYSA-N 0.000 claims 1
- TUXGYOGLJLNSLC-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]-2-phenylethoxy]phenoxy]propanoic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(OC=1C=C(C)C(OC(C)(C)C(O)=O)=CC=1)CC1=CC=CC=C1 TUXGYOGLJLNSLC-UHFFFAOYSA-N 0.000 claims 1
- ACLIMENRFRVCSU-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]but-3-enoxy]phenoxy]propanoic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(CC=C)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 ACLIMENRFRVCSU-UHFFFAOYSA-N 0.000 claims 1
- DOYOGUXJFXYZPD-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]butoxy]phenoxy]propanoic acid Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(CCC)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 DOYOGUXJFXYZPD-UHFFFAOYSA-N 0.000 claims 1
- RRDUKUBKIRKLQP-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenoxy]propanoic acid Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(C)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 RRDUKUBKIRKLQP-UHFFFAOYSA-N 0.000 claims 1
- MEAQHQOZORFODX-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethylsulfanyl]phenoxy]propanoic acid Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(C)SC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 MEAQHQOZORFODX-UHFFFAOYSA-N 0.000 claims 1
- ZOLXTFMSCKSTOO-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]pentoxy]phenoxy]propanoic acid Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(CCCC)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 ZOLXTFMSCKSTOO-UHFFFAOYSA-N 0.000 claims 1
- GPDKHYMYBCWQSD-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propoxy]phenoxy]propanoic acid Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(CC)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 GPDKHYMYBCWQSD-UHFFFAOYSA-N 0.000 claims 1
- SINFYHIOGKADPP-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propylsulfanyl]phenoxy]propanoic acid Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(CC)SC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 SINFYHIOGKADPP-UHFFFAOYSA-N 0.000 claims 1
- UNSKNEREBDWKII-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[2-[2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propan-2-yloxy]phenoxy]propanoic acid Chemical compound C1=C(OC(C)(C)C(O)=O)C(C)=CC(OC(C)(C)C=2SC(=NC=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 UNSKNEREBDWKII-UHFFFAOYSA-N 0.000 claims 1
- HQHRFQAEWBBOAE-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[2-[2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propan-2-ylsulfanyl]phenoxy]propanoic acid Chemical compound C1=C(OC(C)(C)C(O)=O)C(C)=CC(SC(C)(C)C=2SC(=NC=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 HQHRFQAEWBBOAE-UHFFFAOYSA-N 0.000 claims 1
- YIJZPRXQAKJHNE-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propan-2-yloxy]phenoxy]propanoic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(C)(C)OC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 YIJZPRXQAKJHNE-UHFFFAOYSA-N 0.000 claims 1
- MNYRVRCNVSMQRM-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propan-2-ylsulfanyl]phenoxy]propanoic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(C)(C)SC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 MNYRVRCNVSMQRM-UHFFFAOYSA-N 0.000 claims 1
- IVPLIRNRYVHYOT-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]cyclohexa-2,4-dien-1-yl]methoxy]phenoxy]propanoic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C1(COC=2C=C(C)C(OC(C)(C)C(O)=O)=CC=2)CC=CC=C1 IVPLIRNRYVHYOT-UHFFFAOYSA-N 0.000 claims 1
- LQLKLIQPTDBTIF-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methoxy]phenoxy]propanoic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1COC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 LQLKLIQPTDBTIF-UHFFFAOYSA-N 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- ZXHJTFHHPIOPGB-UHFFFAOYSA-N ethyl 2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenoxy]acetate Chemical compound C1=C(C)C(OCC(=O)OCC)=CC=C1OC(C)C1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 ZXHJTFHHPIOPGB-UHFFFAOYSA-N 0.000 claims 1
- DBURNDRLWVLANW-UHFFFAOYSA-N ethyl 2-[4-[1-[2-(3,4-dichlorophenyl)-4-methyl-1,3-thiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OC(C)C1=C(C)N=C(C=2C=C(Cl)C(Cl)=CC=2)S1 DBURNDRLWVLANW-UHFFFAOYSA-N 0.000 claims 1
- HFOMNFSKPLSQCE-UHFFFAOYSA-N ethyl 2-[4-[1-[2-(4-chlorophenyl)-4-methyl-1,3-thiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OC(C)C1=C(C)N=C(C=2C=CC(Cl)=CC=2)S1 HFOMNFSKPLSQCE-UHFFFAOYSA-N 0.000 claims 1
- LWZJOPATGVBMKD-UHFFFAOYSA-N ethyl 2-[4-[1-[2-(4-ethylphenyl)-4-methyl-1,3-thiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OC(C)C1=C(C)N=C(C=2C=CC(CC)=CC=2)S1 LWZJOPATGVBMKD-UHFFFAOYSA-N 0.000 claims 1
- MOCCWJXYISRYQO-UHFFFAOYSA-N ethyl 2-[4-[1-[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]ethoxy]-2-methylphenoxy]-2-methylpropanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OC(C)C1=C(C)N=C(C=2C=C(F)C(=CC=2)C(F)(F)F)S1 MOCCWJXYISRYQO-UHFFFAOYSA-N 0.000 claims 1
- WZLKBWUOLKNURJ-UHFFFAOYSA-N ethyl 2-[4-[cyclopentyl-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methoxy]-2-methylphenoxy]-2-methylpropanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OC(C1=C(N=C(S1)C=1C=CC(=CC=1)C(F)(F)F)C)C1CCCC1 WZLKBWUOLKNURJ-UHFFFAOYSA-N 0.000 claims 1
- VVSDRJWDUWKJEQ-QGZVFWFLSA-N ethyl 2-methyl-2-[2-methyl-4-[(1r)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1O[C@H](C)C1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 VVSDRJWDUWKJEQ-QGZVFWFLSA-N 0.000 claims 1
- DUHMSMHVKCZPHW-OAQYLSRUSA-N ethyl 2-methyl-2-[2-methyl-4-[(1r)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propoxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1O[C@H](CC)C1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 DUHMSMHVKCZPHW-OAQYLSRUSA-N 0.000 claims 1
- VVSDRJWDUWKJEQ-KRWDZBQOSA-N ethyl 2-methyl-2-[2-methyl-4-[(1s)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1O[C@@H](C)C1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 VVSDRJWDUWKJEQ-KRWDZBQOSA-N 0.000 claims 1
- DUHMSMHVKCZPHW-NRFANRHFSA-N ethyl 2-methyl-2-[2-methyl-4-[(1s)-1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propoxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1O[C@@H](CC)C1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 DUHMSMHVKCZPHW-NRFANRHFSA-N 0.000 claims 1
- NEMPFGQAFNBACF-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[1-[2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OC(C)C1=CN=C(C=2C=CC(=CC=2)C(F)(F)F)S1 NEMPFGQAFNBACF-UHFFFAOYSA-N 0.000 claims 1
- QTURWFQIKQVYCZ-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]-2-phenylethoxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OC(C1=C(N=C(S1)C=1C=CC(=CC=1)C(F)(F)F)C)CC1=CC=CC=C1 QTURWFQIKQVYCZ-UHFFFAOYSA-N 0.000 claims 1
- OZAASIUSAUEJBC-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]but-3-enoxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OC(CC=C)C1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 OZAASIUSAUEJBC-UHFFFAOYSA-N 0.000 claims 1
- WBMZDAQGXFDTBQ-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]butoxy]phenoxy]propanoate Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(CCC)OC1=CC=C(OC(C)(C)C(=O)OCC)C(C)=C1 WBMZDAQGXFDTBQ-UHFFFAOYSA-N 0.000 claims 1
- VVSDRJWDUWKJEQ-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OC(C)C1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 VVSDRJWDUWKJEQ-UHFFFAOYSA-N 0.000 claims 1
- UXFXXVKVEXOMHE-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethylsulfanyl]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1SC(C)C1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 UXFXXVKVEXOMHE-UHFFFAOYSA-N 0.000 claims 1
- JOZKDSFBDDGHOS-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]pentoxy]phenoxy]propanoate Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(CCCC)OC1=CC=C(OC(C)(C)C(=O)OCC)C(C)=C1 JOZKDSFBDDGHOS-UHFFFAOYSA-N 0.000 claims 1
- DUHMSMHVKCZPHW-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propoxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OC(CC)C1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 DUHMSMHVKCZPHW-UHFFFAOYSA-N 0.000 claims 1
- JBQDPMDKMBYJDD-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propylsulfanyl]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1SC(CC)C1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 JBQDPMDKMBYJDD-UHFFFAOYSA-N 0.000 claims 1
- WZJRDOUGNQVPHT-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[2-[2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propan-2-yloxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OC(C)(C)C1=CN=C(C=2C=CC(=CC=2)C(F)(F)F)S1 WZJRDOUGNQVPHT-UHFFFAOYSA-N 0.000 claims 1
- WYKFKUGBMNNIEZ-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propan-2-ylsulfanyl]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1SC(C)(C)C1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 WYKFKUGBMNNIEZ-UHFFFAOYSA-N 0.000 claims 1
- WBCQUDYYSJMYGF-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]cyclohexa-2,4-dien-1-yl]methoxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OCC1(C2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)C)C=CC=CC1 WBCQUDYYSJMYGF-UHFFFAOYSA-N 0.000 claims 1
- NCNIULXXTBGJFD-UHFFFAOYSA-N ethyl 2-methyl-2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methoxy]phenoxy]propanoate Chemical compound C1=C(C)C(OC(C)(C)C(=O)OCC)=CC=C1OCC1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 NCNIULXXTBGJFD-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0031107.6A GB0031107D0 (en) | 2000-12-20 | 2000-12-20 | Chemical compounds |
| PCT/US2001/049230 WO2002062774A1 (en) | 2000-12-20 | 2001-12-19 | Thiazole derivatives for treating ppar related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004518702A JP2004518702A (ja) | 2004-06-24 |
| JP2004518702A5 true JP2004518702A5 (https=) | 2005-12-22 |
| JP4209681B2 JP4209681B2 (ja) | 2009-01-14 |
Family
ID=9905492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002562729A Expired - Fee Related JP4209681B2 (ja) | 2000-12-20 | 2001-12-19 | Ｐｐａｒ関連障害治療用のチアゾール誘導体 |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1343773B1 (https=) |
| JP (1) | JP4209681B2 (https=) |
| KR (1) | KR100815022B1 (https=) |
| CN (1) | CN1252057C (https=) |
| AR (1) | AR035522A1 (https=) |
| AT (1) | ATE344253T1 (https=) |
| AU (1) | AU2002246713B2 (https=) |
| BR (1) | BR0116370A (https=) |
| CA (1) | CA2432188A1 (https=) |
| CY (1) | CY1105915T1 (https=) |
| CZ (1) | CZ20031737A3 (https=) |
| DE (1) | DE60124302T2 (https=) |
| DK (1) | DK1343773T3 (https=) |
| ES (1) | ES2274914T3 (https=) |
| GB (1) | GB0031107D0 (https=) |
| HU (1) | HUP0400837A3 (https=) |
| IL (2) | IL156436A0 (https=) |
| MX (1) | MXPA03005699A (https=) |
| MY (1) | MY136685A (https=) |
| NO (1) | NO20032801L (https=) |
| NZ (1) | NZ526543A (https=) |
| PL (1) | PL365797A1 (https=) |
| PT (1) | PT1343773E (https=) |
| SI (1) | SI1343773T1 (https=) |
| TW (1) | TWI292759B (https=) |
| WO (1) | WO2002062774A1 (https=) |
| ZA (1) | ZA200304679B (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| HUP0302397A3 (en) | 2000-05-26 | 2007-02-28 | Nippon Shinyaku Co Ltd | Heterocyclic compounds and pharmaceutical compositions containing them |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| US20040072838A1 (en) | 2000-12-20 | 2004-04-15 | Pierette Banker | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
| IL160327A0 (en) | 2001-08-13 | 2004-07-25 | Janssen Pharmaceutica Nv | 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
| ES2290439T3 (es) | 2002-02-25 | 2008-02-16 | Eli Lilly And Company | Moduladores del receptor activado del proliferador de peroxisomas. |
| ES2316736T3 (es) | 2002-02-25 | 2009-04-16 | Eli Lilly And Company | Moduladores de receptores activados por proliferador de peroxisoma. |
| US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| US6987118B2 (en) * | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
| AU2004247355A1 (en) | 2003-06-06 | 2004-12-23 | F. Hoffmann-La Roche Ag | Aniline derivatives |
| RU2344135C2 (ru) | 2003-07-02 | 2009-01-20 | Ф.Хоффманн-Ля Рош Аг | Тиазолзамещенные индолилпроизводные и их применение в качестве модуляторов ppar |
| EP1667964B1 (en) | 2003-09-19 | 2009-07-22 | Janssen Pharmaceutica N.V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| JP5299810B2 (ja) * | 2004-02-27 | 2013-09-25 | アムジエン・インコーポレーテツド | 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法 |
| US8053598B2 (en) | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
| DE602005024384D1 (de) | 2004-05-05 | 2010-12-09 | High Point Pharmaceuticals Llc | Neue verbindungen, ihre herstellung und verwendung |
| MY147518A (en) | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| MY145712A (en) | 2004-09-15 | 2012-03-30 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| WO2006071103A1 (en) * | 2004-12-31 | 2006-07-06 | Heonjoong Kang | Organoselenium containing compounds and their use |
| EP1856072A4 (en) * | 2005-02-25 | 2009-10-21 | Seoul Nat Univ Ind Foundation | THIAZOLE DERIVATIVES AS PPAR DELTA LIGANDS AND PROCESSES FOR THE PRODUCTION THEREOF |
| CN101146784B (zh) * | 2005-02-25 | 2012-09-05 | 财团法人首尔大学校产学协力财团 | 作为PPARδ配体的噻唑衍生物及其制造方法 |
| US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| ES2372617T3 (es) | 2005-06-30 | 2012-01-24 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de ppar-delta. |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| WO2007033002A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| CN103224477A (zh) | 2005-12-22 | 2013-07-31 | 高点制药有限责任公司 | 作为PPAR-δ活化剂的苯氧基乙酸 |
| CN101007790B (zh) * | 2006-01-27 | 2011-03-30 | 北京摩力克科技有限公司 | 草氨酸衍生物、其制备方法和医药用途 |
| US7943612B2 (en) | 2006-03-09 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds that modulate PPAR activity, their preparation and use |
| UY30288A1 (es) | 2006-04-18 | 2007-08-31 | Janssen Pharmaceutica Nv | Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol |
| CA2662305C (en) | 2006-09-07 | 2012-04-17 | Amgen Inc. | Heterocyclic gpr40 modulators |
| AU2007292816B2 (en) | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| US8519145B2 (en) | 2006-12-02 | 2013-08-27 | Seoul National University Industry Foundation | Aryl compounds as PPAR ligands and their use |
| RU2444518C2 (ru) * | 2007-01-08 | 2012-03-10 | Сеул Нэшнл Юниверсити Индастри Фаундейшн | ПРОИЗВОДНОЕ ТИАЗОЛА КАК PPARδ ЛИГАНД И ФАРМАЦЕВТИЧЕСКИЙ, КОСМЕТИЧЕСКИЙ И ДИЕТИЧЕСКИЙ ПИЩЕВОЙ ПРОДУКТ, СОДЕРЖАЩИЙ ЕГО |
| PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| EP2139843B1 (en) | 2007-04-16 | 2013-12-25 | Amgen, Inc | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
| CN102083783A (zh) | 2007-10-10 | 2011-06-01 | 安姆根有限公司 | 取代的联苯gpr40调节剂 |
| WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| EP2540711A4 (en) * | 2010-02-25 | 2014-01-22 | Snu R&Db Foundation | Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds |
| US20120094959A1 (en) | 2010-10-19 | 2012-04-19 | Bonnie Blazer-Yost | Treatment of cystic diseases |
| EP3756661A1 (en) | 2013-09-09 | 2020-12-30 | vTv Therapeutics LLC | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434164A (en) * | 1981-06-01 | 1984-02-28 | Pfizer Inc. | Crystalline benzothiazine dioxide salts |
| US4623486A (en) * | 1985-05-29 | 1986-11-18 | Pfizer Inc. | [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
-
2000
- 2000-12-20 GB GBGB0031107.6A patent/GB0031107D0/en not_active Ceased
-
2001
- 2001-12-18 TW TW090131348A patent/TWI292759B/zh active
- 2001-12-18 AR ARP010105863A patent/AR035522A1/es not_active Application Discontinuation
- 2001-12-19 DK DK01994305T patent/DK1343773T3/da active
- 2001-12-19 BR BR0116370-1A patent/BR0116370A/pt not_active IP Right Cessation
- 2001-12-19 KR KR1020037008392A patent/KR100815022B1/ko not_active Expired - Fee Related
- 2001-12-19 ES ES01994305T patent/ES2274914T3/es not_active Expired - Lifetime
- 2001-12-19 DE DE60124302T patent/DE60124302T2/de not_active Expired - Fee Related
- 2001-12-19 PL PL01365797A patent/PL365797A1/xx not_active Application Discontinuation
- 2001-12-19 IL IL15643601A patent/IL156436A0/xx active IP Right Grant
- 2001-12-19 CN CNB018223095A patent/CN1252057C/zh not_active Expired - Fee Related
- 2001-12-19 CZ CZ20031737A patent/CZ20031737A3/cs unknown
- 2001-12-19 AT AT01994305T patent/ATE344253T1/de not_active IP Right Cessation
- 2001-12-19 MY MYPI20015760A patent/MY136685A/en unknown
- 2001-12-19 AU AU2002246713A patent/AU2002246713B2/en not_active Ceased
- 2001-12-19 MX MXPA03005699A patent/MXPA03005699A/es active IP Right Grant
- 2001-12-19 SI SI200130672T patent/SI1343773T1/sl unknown
- 2001-12-19 EP EP01994305A patent/EP1343773B1/en not_active Expired - Lifetime
- 2001-12-19 HU HU0400837A patent/HUP0400837A3/hu unknown
- 2001-12-19 PT PT01994305T patent/PT1343773E/pt unknown
- 2001-12-19 WO PCT/US2001/049230 patent/WO2002062774A1/en not_active Ceased
- 2001-12-19 JP JP2002562729A patent/JP4209681B2/ja not_active Expired - Fee Related
- 2001-12-19 NZ NZ526543A patent/NZ526543A/en unknown
- 2001-12-19 CA CA002432188A patent/CA2432188A1/en not_active Abandoned
-
2003
- 2003-06-12 IL IL156436A patent/IL156436A/en not_active IP Right Cessation
- 2003-06-17 ZA ZA200304679A patent/ZA200304679B/en unknown
- 2003-06-19 NO NO20032801A patent/NO20032801L/no not_active Application Discontinuation
-
2007
- 2007-01-10 CY CY20071100032T patent/CY1105915T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004518702A5 (https=) | ||
| JP4209681B2 (ja) | Ｐｐａｒ関連障害治療用のチアゾール誘導体 | |
| JP4234431B2 (ja) | ヒトペルオキシソーム増殖因子活性化受容体の活性化剤としてのチアゾール及びオキサゾール誘導体 | |
| JP3490704B2 (ja) | チアゾールおよびオキサゾール誘導体ならびにそれらの医薬的使用 | |
| JP2004534035A5 (https=) | ||
| US7649110B2 (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
| JP2005509590A6 (ja) | ペルオキシソーム増殖因子活性化受容体の調節物質 | |
| JP2005509590A5 (https=) | ||
| JP2005509590A (ja) | ペルオキシソーム増殖因子活性化受容体の調節物質 | |
| SK1962001A3 (en) | Substituted oxazoles and thiazoles derivatives as hppar gamma and hppar alpha activators | |
| JP2004532266A (ja) | 心血管系疾患の治療に有用なチアゾールまたはオキサゾール誘導体 | |
| US7241793B2 (en) | Phenyloxyalkanonic acid derivatives as hPPAR activators | |
| JP2004517100A5 (https=) | ||
| JP2007527416A5 (https=) | ||
| JP2007531764A5 (https=) | ||
| JP2007522178A5 (https=) | ||
| US7141591B2 (en) | 1,2,4-oxadiazole derivatives as hPPAR alpha agonists | |
| CA2571722A1 (en) | Phenyl derivatives comprising an acetylene group | |
| US7439259B2 (en) | Thiazole derivatives for treating PPAR related disorders | |
| US20070225294A1 (en) | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | |
| HK1059925B (en) | Thiazole derivatives for treating ppar related disorders | |
| MXPA01001419A (en) | SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS |